Efficacy of sotrovimab on omicron BA.2, BA.4 and BA.5 subvariants of sars-cov-2 vs. other early therapies: a...

Area of Science:

• Infectious Diseases
• Virology
• Clinical Pharmacology

Background:

• Evaluating sotrovimab's efficacy against COVID-19 Omicron BA.2, BA.4, and BA.5 subvariants.
• Comparing sotrovimab to other antivirals for high-risk COVID-19 patients.
• Assessing impact on hospitalization and mortality rates.

Approach:

• Systematic review and meta-analysis of RCTs and observational studies.
• Searched MEDLINE, Google Scholar, and Cochrane Library adhering to PRISMA guidelines.
• Included four studies with 8,041 patients.

Key Points:

• Meta-analysis revealed no statistically significant difference in hospitalization or mortality between sotrovimab and other treatments.
• Relative Risk (RR) for mortality: OR 0.38, 95% CI 0.10-1.49, p=0.166.
• Hospitalization rate: OR 1.66, 95% CI 0.41-6.66, p=0.477.

Conclusions:

• Sotrovimab demonstrated no significant advantage over other antivirals in preventing COVID-19 progression, hospitalization, or mortality.
• Findings apply to patients with high risk of progression during Omicron BA.2, BA.4, and BA.5 waves.
• Further research may be needed to clarify optimal antiviral strategies.